Limited studies were carried on the immune response in BM of AML patients; although in a majority of patients, AML is derived from myeloid hematopoietic progenitors and rapidly grows in BM before mobilizing to peripheral blood; therefore understanding the anti‐leukemia immune response within the BM of AML patients is likely to be a key to develop immune therapeutics for leukemia, and therefore in this study, we investigated the inhibitory checkpoint (PD‐1) T cell within BM of AML patients [11]. Here, PDCD1 is linked to acute myeloid leukemia.